Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brainstorm Cell Therapeutics hires leading scientist to advisory board

This article was originally published in Clinica

Executive Summary

Brainstorm Cell Therapeutics, a firm focused on developing adult stem cell technologies and therapeutics for treatment of neurological conditions, has appointed Robert Brown to its scientific advisory board. Dr Brown, a professor of neurology at Harvard Medical School and Massachusetts General Hospital (MGH), is an expert in amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). He will help the New York, New York based company develop protocols for testing its lead products as ALS therapies. During his 30 years in the field, he has founded the Cecil Bay Laboratory for neuromuscular research at MGH and had his research published widely. In 2007 he won the Robert Wartenberg Lecture Award for excellence in clinically-relevant research, and will become chair of the medical school at the University of Massachusetts later this year.

You may also be interested in...

Asia Regulatory Forum Update

Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.

Saudi Arabia adopts interim device authorisation regulation

Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.

Canada takes action to increase more adverse event reporting

The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts